https://www.yiliao.com/index.php?action=history&feed=atom&title=POLD1
POLD1 - 版本历史
2026-04-18T11:17:00Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=POLD1&diff=311947&oldid=prev
2025年12月30日 (二) 08:25 77921020
2025-12-30T08:25:12Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月30日 (二) 08:25的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l3" >第3行：</td>
<td colspan="2" class="diff-lineno">第3行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <strong>POLD1</strong>（DNA Polymerase Delta 1, Catalytic Subunit），编码<strong>DNA 聚合酶 <del class="diffchange diffchange-inline">$\delta$</del></strong> 的催化亚基（p125）。这是真核细胞 DNA 复制和修复机器中的核心组件，主要负责<strong>后随链</strong>（Lagging Strand）的高保真合成及多种 DNA 修复过程（如 NER 和 <del class="diffchange diffchange-inline">BER）。POLD1 </del>蛋白拥有两个关键活性：5'→3' 聚合酶活性（合成 DNA）和 <strong>3'→5' 外切酶活性</strong>（校对/Proofreading）。在临床遗传学和肿瘤学中，POLD1 具有里程碑式的意义：其外切酶结构域（Exonuclease Domain）的生殖系突变导致一种高外显率的癌症易感综合征——<strong>[[聚合酶校对相关息肉病]] (PPAP)</strong><del class="diffchange diffchange-inline">，患者极易早发结直肠癌和子宫内膜癌。而在体细胞层面，POLD1 </del>突变的肿瘤表现为“<strong>超突变</strong><del class="diffchange diffchange-inline">”（Ultramutated）表型，具有极高的肿瘤突变负荷（TMB），因此对免疫检查点抑制剂（ICI）治疗反应极佳。</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <strong>POLD1</strong>（DNA Polymerase Delta 1, Catalytic Subunit），编码<strong>DNA 聚合酶 <ins class="diffchange diffchange-inline">δ</ins></strong> <ins class="diffchange diffchange-inline">(Delta) </ins>的催化亚基（p125）。这是真核细胞 DNA 复制和修复机器中的核心组件，主要负责<strong>后随链</strong>（Lagging Strand）的高保真合成及多种 DNA 修复过程（如 <ins class="diffchange diffchange-inline">[[</ins>NER<ins class="diffchange diffchange-inline">]] </ins>和 <ins class="diffchange diffchange-inline">[[BER]]）。POLD1 </ins>蛋白拥有两个关键活性：5'→3' 聚合酶活性（合成 DNA）和 <strong>3'→5' 外切酶活性</strong>（校对/Proofreading）。在临床遗传学和肿瘤学中，POLD1 具有里程碑式的意义：其外切酶结构域（Exonuclease Domain）的生殖系突变导致一种高外显率的癌症易感综合征——<strong>[[聚合酶校对相关息肉病]] (PPAP)</strong><ins class="diffchange diffchange-inline">，患者极易早发[[结直肠癌]]和[[子宫内膜癌]]。而在体细胞层面，POLD1 </ins>突变的肿瘤表现为“<strong>超突变</strong><ins class="diffchange diffchange-inline">”（Ultramutated）表型，具有极高的肿瘤突变负荷（[[TMB]]），因此对<strong>[[免疫检查点抑制剂]]</strong>（ICI）治疗反应极佳。</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l67" >第67行：</td>
<td colspan="2" class="diff-lineno">第67行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>复制分工 (Division of Labor)：</strong> 在真核生物 DNA 复制叉处，Pol <del class="diffchange diffchange-inline">$\epsilon$ </del>(POLE) 主要负责前导链 (Leading strand) 的连续合成，而 <strong>Pol <del class="diffchange diffchange-inline">$\delta$ </del>(POLD1)</strong> 主要负责<strong>后随链 (Lagging strand)</strong> 冈崎片段的不连续合成。POLD1 也是 DNA 修复（核苷酸切除修复 <del class="diffchange diffchange-inline">NER、碱基切除修复 BER、错配修复 MMR）中的主要合成酶。</del></li></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>复制分工 (Division of Labor)：</strong> 在真核生物 DNA 复制叉处，Pol <ins class="diffchange diffchange-inline">ε </ins>(POLE) 主要负责前导链 (Leading strand) 的连续合成，而 <strong>Pol <ins class="diffchange diffchange-inline">δ </ins>(POLD1)</strong> 主要负责<strong>后随链 (Lagging strand)</strong> 冈崎片段的不连续合成。POLD1 也是 DNA 修复（核苷酸切除修复 <ins class="diffchange diffchange-inline">[[NER]]、碱基切除修复 [[BER]]、错配修复 [[MMR]]）中的主要合成酶。</ins></li></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>全酶结构：</strong> POLD1 是 Pol <del class="diffchange diffchange-inline">$\delta$ </del>的催化亚基，它与调节亚基 POLD2 (p50)、POLD3 (p66) 和 POLD4 (p12) 形成异源四聚体。其功能发挥高度依赖于滑动夹 <strong>PCNA</strong>（增殖细胞核抗原），PCNA 将 POLD1 锚定在 DNA 上以提高持续合成能力。</li></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>全酶结构：</strong> POLD1 是 Pol <ins class="diffchange diffchange-inline">δ </ins>的催化亚基，它与调节亚基 POLD2 (p50)、POLD3 (p66) 和 POLD4 (p12) 形成异源四聚体。其功能发挥高度依赖于滑动夹 <strong><ins class="diffchange diffchange-inline">[[</ins>PCNA<ins class="diffchange diffchange-inline">]]</ins></strong>（增殖细胞核抗原），PCNA 将 POLD1 锚定在 DNA 上以提高持续合成能力。</li></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>校对活性 (Proofreading)：</strong> POLD1 拥有一个至关重要的 <strong>3'→5' 外切酶结构域</strong>。当聚合酶错误地掺入了不配对的碱基时，该结构域就像“退格键”一样，能够识别并切除错误的核苷酸，确保复制的高保真性。如果该结构域突变（如 <del class="diffchange diffchange-inline">S478N），复制错误率会飙升 </del>100 倍以上，导致基因组<strong>突变灾难</strong>。</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>校对活性 (Proofreading)：</strong> POLD1 拥有一个至关重要的 <strong>3'→5' 外切酶结构域</strong>。当聚合酶错误地掺入了不配对的碱基时，该结构域就像“退格键”一样，能够识别并切除错误的核苷酸，确保复制的高保真性。如果该结构域突变（如 <ins class="diffchange diffchange-inline"><strong>S478N</strong>），复制错误率会飙升 </ins>100 倍以上，导致基因组<strong>突变灾难</strong>。</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </li></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </li></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l86" >第86行：</td>
<td colspan="2" class="diff-lineno">第86行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><del class="diffchange diffchange-inline">PPAP 综合征</del></td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><ins class="diffchange diffchange-inline">[[PPAP综合征]]</ins></td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">生殖系 <strong>S478N</strong> 突变</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">生殖系 <strong>S478N</strong> 突变</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">全称<strong>聚合酶校对相关息肉病</strong>。由 POLD1 或 POLE 外切酶域的生殖系突变引起。为常染色体显性遗传。患者表现为多发性结直肠腺瘤（息肉负荷通常少于 <del class="diffchange diffchange-inline">FAP，类似 MAP），且在 </del>50 岁前患<strong>结直肠癌</strong>和<strong>子宫内膜癌</strong>的风险极高。</td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">全称<strong>聚合酶校对相关息肉病</strong>。由 POLD1 或 <ins class="diffchange diffchange-inline">[[</ins>POLE<ins class="diffchange diffchange-inline">]] </ins>外切酶域的生殖系突变引起。为常染色体显性遗传。患者表现为多发性结直肠腺瘤（息肉负荷通常少于 <ins class="diffchange diffchange-inline">[[FAP]]，类似 [[MAP]]），且在 </ins>50 岁前患<strong><ins class="diffchange diffchange-inline">[[</ins>结直肠癌<ins class="diffchange diffchange-inline">]]</ins></strong>和<strong><ins class="diffchange diffchange-inline">[[</ins>子宫内膜癌<ins class="diffchange diffchange-inline">]]</ins></strong>的风险极高。</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">散发性结直肠癌 (CRC)</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">散发性结直肠癌 (CRC)</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞外切酶域突变</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞外切酶域突变</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">导致“<strong>超突变</strong>” (Ultramutated) 表型（TMB > 100 mut/Mb），甚至高于 MSI-H 肿瘤。尽管突变负荷极高，但这部分患者的预后通常较好，且对免疫治疗反应极佳。</td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">导致“<strong>超突变</strong>” (Ultramutated) 表型（TMB > 100 mut/Mb），甚至高于 <ins class="diffchange diffchange-inline">[[</ins>MSI-H<ins class="diffchange diffchange-inline">]] </ins>肿瘤。尽管突变负荷极高，但这部分患者的预后通常较好，且对免疫治疗反应极佳。</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">子宫内膜癌</td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><ins class="diffchange diffchange-inline">[[</ins>子宫内膜癌<ins class="diffchange diffchange-inline">]]</ins></td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">POLE/POLD1 突变</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">POLE/POLD1 突变</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">在 TCGA 分型中，POLE/POLD1 超突变型是一类具有独特分子特征和极好预后的亚型，通常不需要过度的辅助放化疗。</td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">在 <ins class="diffchange diffchange-inline">[[</ins>TCGA<ins class="diffchange diffchange-inline">]] </ins>分型中，POLE/POLD1 超突变型是一类具有独特分子特征和极好预后的亚型，通常不需要过度的辅助放化疗。</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </table></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </table></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l108" >第108行：</td>
<td colspan="2" class="diff-lineno">第108行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>免疫检查点抑制剂 (ICIs)：</strong></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong><ins class="diffchange diffchange-inline">[[</ins>免疫检查点抑制剂<ins class="diffchange diffchange-inline">]] </ins>(ICIs)：</strong></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <br><strong>[[Pembrolizumab]]</strong> (帕博利珠单抗), <strong>Nivolumab</strong> (纳武利尤单抗)。</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <br><strong>[[Pembrolizumab]]</strong> (帕博利珠单抗), <strong>Nivolumab</strong> (纳武利尤单抗)。</div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <br><span style="font-size: 0.9em; color: #64748b;">*原理：POLD1 校对功能缺失导致肿瘤积累了成千上万的体细胞突变。这些突变产生了大量异常的肽段（<strong>新抗原 / Neoantigens</strong><del class="diffchange diffchange-inline">），使得肿瘤具有极高的免疫原性。大量淋巴细胞浸润肿瘤（TILs），但在治疗前常被 </del>PD-1/L1 抑制。使用 ICIs 解除抑制后，免疫系统会猛烈攻击肿瘤。</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <br><span style="font-size: 0.9em; color: #64748b;">*原理：POLD1 校对功能缺失导致肿瘤积累了成千上万的体细胞突变。这些突变产生了大量异常的肽段（<strong><ins class="diffchange diffchange-inline">[[</ins>新抗原<ins class="diffchange diffchange-inline">]] </ins>/ Neoantigens</strong><ins class="diffchange diffchange-inline">），使得肿瘤具有极高的免疫原性。大量淋巴细胞浸润肿瘤（[[TILs]]），但在治疗前常被 </ins>PD-1/L1 抑制。使用 ICIs 解除抑制后，免疫系统会猛烈攻击肿瘤。</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <br>*疗效：POLD1/POLE 突变患者通常是 ICIs 的“超级响应者”，疗效优于 MSI-H 患者。</span></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <br>*疗效：POLD1/POLE 突变患者通常是 ICIs 的“超级响应者”，疗效优于 MSI-H 患者。</span></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </li></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </li></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>遗传咨询与筛查：</strong></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>遗传咨询与筛查：</strong></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <br>对于早发性 CRC 或多发性息肉但 MMR <del class="diffchange diffchange-inline">基因（林奇综合征）检测阴性的患者，必须筛查 </del>POLD1 和 POLE 的外切酶域突变。确诊 PPAP 的患者及其家属需要高频的肠镜和子宫内膜癌筛查。</li></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <br>对于早发性 CRC 或多发性息肉但 MMR <ins class="diffchange diffchange-inline">基因（[[林奇综合征]]）检测阴性的患者，必须筛查 </ins>POLD1 和 POLE 的外切酶域突变。确诊 PPAP 的患者及其家属需要高频的肠镜和子宫内膜癌筛查。</li></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </ul></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </ul></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong><del class="diffchange diffchange-inline">PPAP：</del></strong> 聚合酶校对相关息肉病，POLD1/POLE 突变导致的新综合征。</li></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong><ins class="diffchange diffchange-inline">[[PPAP综合征]]：</ins></strong> 聚合酶校对相关息肉病，POLD1/POLE 突变导致的新综合征。</li></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>校对 (Proofreading)：</strong> 3'→5' 外切酶活性，DNA 复制保真度的核心。</li></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>校对 (Proofreading)：</strong> 3'→5' 外切酶活性，DNA 复制保真度的核心。</li></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>超突变 (Ultramutation)：</strong> POLD1 失活导致的极端高 TMB 状态。</li></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>超突变 (Ultramutation)：</strong> POLD1 失活导致的极端高 TMB 状态。</li></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l134" >第134行：</td>
<td colspan="2" class="diff-lineno">第134行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> [2] <strong>Briggs S, Tomlinson I. (2013).</strong> <em>Germline and somatic polymerase <del class="diffchange diffchange-inline">$\epsilon$ </del>and <del class="diffchange diffchange-inline">$\delta$ </del>mutations define a new class of hypermutated colorectal and endometrial cancers.</em> <strong>Journal of Pathology</strong>. <br></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> [2] <strong>Briggs S, Tomlinson I. (2013).</strong> <em>Germline and somatic polymerase <ins class="diffchange diffchange-inline">ε </ins>and <ins class="diffchange diffchange-inline">δ </ins>mutations define a new class of hypermutated colorectal and endometrial cancers.</em> <strong>Journal of Pathology</strong>. <br></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #475569;">[学术点评]：综述与分类。详细阐述了 POLD1/POLE 突变肿瘤的分子病理特征，将其与 MSI-H 肿瘤区分开来，强调了其极高的突变负荷和独特的突变谱（Signature 10）。</span></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #475569;">[学术点评]：综述与分类。详细阐述了 POLD1/POLE 突变肿瘤的分子病理特征，将其与 MSI-H 肿瘤区分开来，强调了其极高的突变负荷和独特的突变谱（Signature 10）。</span></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=POLD1&diff=311946&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-30T08:22:59Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>POLD1</strong>（DNA Polymerase Delta 1, Catalytic Subunit），编码<strong>DNA 聚合酶 $\delta$</strong> 的催化亚基（p125）。这是真核细胞 DNA 复制和修复机器中的核心组件，主要负责<strong>后随链</strong>（Lagging Strand）的高保真合成及多种 DNA 修复过程（如 NER 和 BER）。POLD1 蛋白拥有两个关键活性：5'→3' 聚合酶活性（合成 DNA）和 <strong>3'→5' 外切酶活性</strong>（校对/Proofreading）。在临床遗传学和肿瘤学中，POLD1 具有里程碑式的意义：其外切酶结构域（Exonuclease Domain）的生殖系突变导致一种高外显率的癌症易感综合征——<strong>[[聚合酶校对相关息肉病]] (PPAP)</strong>，患者极易早发结直肠癌和子宫内膜癌。而在体细胞层面，POLD1 突变的肿瘤表现为“<strong>超突变</strong>”（Ultramutated）表型，具有极高的肿瘤突变负荷（TMB），因此对免疫检查点抑制剂（ICI）治疗反应极佳。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 340px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">POLD1 · 基因档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gene & Protein Profile (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<br />
[[文件:DNA_Polymerase_Delta_Mechanism.png|100px|Pol δ 在复制叉的功能]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">DNA 复制校对者</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc; width: 40%;">基因符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;"><strong>POLD1</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">全称</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">DNA Polymerase Delta 1, Catalytic Subunit</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">染色体位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">19q13.33</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">Entrez ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">5424</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">HGNC ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">9175</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">UniProt</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">P28340</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">~125 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; color: #475569; background-color: #f8fafc;">复合体</th><br />
<td style="padding: 8px 12px; color: #0f172a;">Pol δ (POLD1-4)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：后随链合成与“退格键”</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
DNA 复制的极高保真度依赖于聚合酶的选择性和校对功能，POLD1 在其中扮演着不可替代的角色。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>复制分工 (Division of Labor)：</strong> 在真核生物 DNA 复制叉处，Pol $\epsilon$ (POLE) 主要负责前导链 (Leading strand) 的连续合成，而 <strong>Pol $\delta$ (POLD1)</strong> 主要负责<strong>后随链 (Lagging strand)</strong> 冈崎片段的不连续合成。POLD1 也是 DNA 修复（核苷酸切除修复 NER、碱基切除修复 BER、错配修复 MMR）中的主要合成酶。</li><br />
<li style="margin-bottom: 12px;"><strong>全酶结构：</strong> POLD1 是 Pol $\delta$ 的催化亚基，它与调节亚基 POLD2 (p50)、POLD3 (p66) 和 POLD4 (p12) 形成异源四聚体。其功能发挥高度依赖于滑动夹 <strong>PCNA</strong>（增殖细胞核抗原），PCNA 将 POLD1 锚定在 DNA 上以提高持续合成能力。</li><br />
<li style="margin-bottom: 12px;"><strong>校对活性 (Proofreading)：</strong> POLD1 拥有一个至关重要的 <strong>3'→5' 外切酶结构域</strong>。当聚合酶错误地掺入了不配对的碱基时，该结构域就像“退格键”一样，能够识别并切除错误的核苷酸，确保复制的高保真性。如果该结构域突变（如 S478N），复制错误率会飙升 100 倍以上，导致基因组<strong>突变灾难</strong>。<br />
<br />
</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床景观：PPAP 综合征与超突变肿瘤</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
POLD1 突变的临床意义主要体现在一种新定义的遗传性癌症综合征和免疫治疗的预测上。<br />
</p><br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">变异特征</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">PPAP 综合征</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">生殖系 <strong>S478N</strong> 突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">全称<strong>聚合酶校对相关息肉病</strong>。由 POLD1 或 POLE 外切酶域的生殖系突变引起。为常染色体显性遗传。患者表现为多发性结直肠腺瘤（息肉负荷通常少于 FAP，类似 MAP），且在 50 岁前患<strong>结直肠癌</strong>和<strong>子宫内膜癌</strong>的风险极高。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">散发性结直肠癌 (CRC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞外切酶域突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">导致“<strong>超突变</strong>” (Ultramutated) 表型（TMB > 100 mut/Mb），甚至高于 MSI-H 肿瘤。尽管突变负荷极高，但这部分患者的预后通常较好，且对免疫治疗反应极佳。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">子宫内膜癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">POLE/POLD1 突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在 TCGA 分型中，POLE/POLD1 超突变型是一类具有独特分子特征和极好预后的亚型，通常不需要过度的辅助放化疗。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：免疫治疗的“超级响应者”</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
POLD1 突变导致的基因组不稳定性虽然驱动了癌症发生，但也成为了肿瘤最大的弱点。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>免疫检查点抑制剂 (ICIs)：</strong><br />
<br><strong>[[Pembrolizumab]]</strong> (帕博利珠单抗), <strong>Nivolumab</strong> (纳武利尤单抗)。<br />
<br><span style="font-size: 0.9em; color: #64748b;">*原理：POLD1 校对功能缺失导致肿瘤积累了成千上万的体细胞突变。这些突变产生了大量异常的肽段（<strong>新抗原 / Neoantigens</strong>），使得肿瘤具有极高的免疫原性。大量淋巴细胞浸润肿瘤（TILs），但在治疗前常被 PD-1/L1 抑制。使用 ICIs 解除抑制后，免疫系统会猛烈攻击肿瘤。<br />
<br>*疗效：POLD1/POLE 突变患者通常是 ICIs 的“超级响应者”，疗效优于 MSI-H 患者。</span><br />
</li><br />
<li style="margin-bottom: 12px;"><strong>遗传咨询与筛查：</strong><br />
<br>对于早发性 CRC 或多发性息肉但 MMR 基因（林奇综合征）检测阴性的患者，必须筛查 POLD1 和 POLE 的外切酶域突变。确诊 PPAP 的患者及其家属需要高频的肠镜和子宫内膜癌筛查。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>PPAP：</strong> 聚合酶校对相关息肉病，POLD1/POLE 突变导致的新综合征。</li><br />
<li style="margin-bottom: 12px;"><strong>校对 (Proofreading)：</strong> 3'→5' 外切酶活性，DNA 复制保真度的核心。</li><br />
<li style="margin-bottom: 12px;"><strong>超突变 (Ultramutation)：</strong> POLD1 失活导致的极端高 TMB 状态。</li><br />
<li style="margin-bottom: 12px;"><strong>S478N：</strong> POLD1 最经典的致病性生殖系突变位点。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Palles C, et al. (2013).</strong> <em>Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.</em> <strong>Nature Genetics</strong>. <br><br />
<span style="color: #475569;">[学术点评]：开创性发现。首次鉴定了 POLE (L424V) 和 POLD1 (S478N) 生殖系突变是导致家族性结直肠癌和息肉病的新原因，正式定义了 PPAP 综合征。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Briggs S, Tomlinson I. (2013).</strong> <em>Germline and somatic polymerase $\epsilon$ and $\delta$ mutations define a new class of hypermutated colorectal and endometrial cancers.</em> <strong>Journal of Pathology</strong>. <br><br />
<span style="color: #475569;">[学术点评]：综述与分类。详细阐述了 POLD1/POLE 突变肿瘤的分子病理特征，将其与 MSI-H 肿瘤区分开来，强调了其极高的突变负荷和独特的突变谱（Signature 10）。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Cancer Genome Atlas Network. (2012).</strong> <em>Comprehensive molecular characterization of human colon and rectal cancer.</em> <strong>Nature</strong>. <br><br />
<span style="color: #475569;">[学术点评]：TCGA 大数据。利用高通量测序，在结直肠癌中识别出了一组具有“超突变”表型的肿瘤，这组肿瘤富集了 POLE/POLD1 的体细胞校对域突变。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Gong J, et al. (2017).</strong> <em>Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.</em> <strong>JAMA Oncology</strong>. <br><br />
<span style="color: #475569;">[学术点评]：临床实证。证明了即使是微卫星稳定（MSS）的患者，只要携带聚合酶校对突变，也能从 PD-1 抑制剂治疗中获得显著获益，改写了 MSS CRC 免疫治疗无效的教条。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[5] <strong>Rayner, E., et al. (2016).</strong> <em>A Pan-cancer Catalogue of Somatic Mutations in Exonuclease Domains of POLD1 and POLE Proteins.</em> <strong>Clinical Cancer Research</strong>. <br><br />
<span style="color: #475569;">[学术点评]：泛癌种分析。系统分析了多种癌症中 POLD1/POLE 的突变频率和类型，证实了这些突变在子宫内膜癌和结直肠癌之外也存在，虽然频率较低。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">POLD1 · 知识图谱关联</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2.2; text-align: center; text-decoration: none;"><br />
[[结直肠癌]] • [[PPAP综合征]] • [[POLE]] • [[超突变]] • [[免疫检查点抑制剂]] • [[子宫内膜癌]] • [[DNA复制]] • [[林奇综合征]]<br />
</div><br />
</div><br />
<br />
</div></div>
77921020